Can-Fite in 2025: The Clinical Calendar Is Filling Up, but Financing Still Runs the Story

Understanding the Company

Can-Fite is not a revenue story. It is a time-financing story. What the company is effectively selling today is not a commercial product but the chance to reach another clinical readout before cash pressure forces a harder funding decision. That is the right way to read 2025. On one side, the calendar is becoming more populated: pancreatic cancer moved from setup to full enrollment, psoriasis and HCC are now sitting inside Phase III paths, and MASH remains active. On the other side, the business still looks like a pre-revenue biotech in the strict sense: $0.405 million of revenue, a $9.8 million net loss, and $8.95 million of negative operating cash flow.

What is working now? The company has turned 2026 from a relatively empty year into a bridge year with a live catalyst. Namodenoson in pancreatic cancer completed enrollment in January 2026, the primary safety endpoint has already been met, and topline data is expected in Q3 2026. That gives the market a nearer event than it had before. At the same time, Piclidenoson in psoriasis and Namodenoson in HCC are both moving through heavier registration-oriented paths.

What is easy to misread on a first pass? The breadth of the indication set and the partner map. On paper, this looks like a diversified platform with several development lanes and multiple distribution partners. The financial statements tell a much more modest story. Reported revenue is almost entirely slow accounting recognition of old upfront payments under legacy agreements. There are no product sales, no commercial traction, and no internal sales infrastructure. The company explicitly says it does not currently have sales, marketing or distribution capabilities and does not expect to build them itself. So even if one of the programs succeeds clinically, value does not automatically flow into the income statement. There is still another gate to cross: a partner, a regulatory event, or a broader monetization step.

The active bottleneck is financial, not just scientific. At year-end 2025 the company had $5.53 million of cash and cash equivalents and another $3.01 million of short-term deposits, or $8.54 million of available liquidity. That is roughly the same order of magnitude as its annual operating cash burn. March 2026 was therefore not a bonus. It was a bridge transaction: a reduced-price warrant exercise that brought in about $4.0 million of gross proceeds while creating a new and larger warrant layer behind it. That is extra time, not an exit from the loop.

There is also a practical actionability constraint. The local market capitalization stands at roughly NIS 21.8 million, while turnover on the latest trading day was only about NIS 6.5 thousand. The whole share base is technically in the float, but 100% float on paper does not create real tradability. After the 1-for-3,000 reverse split at the start of January 2026, the annual report itself warns that trading depth may weaken. Add the continuing NYSE American listing sensitivity, and this becomes a micro-cap where capital structure matters almost as much as the science.

The quick map looks like this:

Events and Triggers

Pancreatic cancer has moved from distant option to near-term catalyst

The first trigger: pancreatic cancer. In January 2026 the company completed patient enrollment in its Phase IIa study in advanced pancreatic adenocarcinoma after at least one prior line of therapy. The study enrolled 20 evaluable patients, all receiving oral Namodenoson at 25 mg twice daily in continuous 28-day cycles, with safety as the primary endpoint.

The key point is that the company has already reported that this primary endpoint was met. In March 2026 it said the drug was well tolerated, no new safety signals were identified, and one-third of patients were still alive at the data cut-off. That gives the market something to work with, but it also creates a clear risk of over-reading the event. A study whose primary endpoint is safety does not become a commercial story simply because safety held up. For Q3 2026 to really matter, the market will need more than tolerability. It will need a signal that can support a real next step.

Psoriasis remains the cleanest commercial path, but it is still not clean

The second trigger: Piclidenoson in psoriasis. This is the company’s most commercially understandable path, which is exactly why it matters so much. Two things are true at the same time. First, the Phase III COMFORT study reported in 2022 met its primary endpoint against placebo at week 16, and by week 48 Piclidenoson reached PASI 50 in 90% of patients, PASI 90 in 10%, and PDI improvement in 60%. Second, at week 32 the drug was inferior to Otezla on PASI 75 and PASI 50. In other words, the safety and tolerability narrative is strong, but the efficacy narrative is still not fully closed.

That is why the company could not simply say the program had already been de-risked. After positive interactions with the FDA and EMA, it started a new pivotal Phase III study in the first quarter of 2025, with co-primary endpoints of PASI 75 and sPGA 0 or 1 at week 16, and interim data expected in Q2 2027. So even in the company’s most advanced commercial lane, Can-Fite still needs to prove that the combination of oral dosing, safety and efficacy is good enough for a registration path.

HCC is built on a subgroup read, not on a full-population win

The third trigger: HCC. This story is more conditional than the mere phrase “Phase III ongoing” suggests. In the prior Phase II study, Namodenoson did not meet the primary endpoint in the full population. Median overall survival was 4.1 months versus 4.3 months for placebo. The positive signal appeared in the CPB7 subgroup, where median overall survival was 6.8 months versus 4.3 months, and one-year survival was 44% versus 18%.

That is not a footnote. It is the core risk. The ongoing LIVERATION Phase III study, which is enrolling about 450 HCC patients with underlying CPB7 cirrhosis, is built directly on that read-through. So the company is effectively taking a promising subgroup signal and asking it to carry a global registration-oriented program. If that works, it could be meaningful. If it fails to replicate, a large part of the Namodenoson equity story weakens with it.

The March 2026 financing bought time and rebuilt the overhang

The fourth trigger: financing. On March 4, 2026 the company signed an inducement letter for the immediate cash exercise of warrants covering 795,869 ADSs at a reduced price of $5.00 per ADS, a transaction expected to generate about $4.0 million of gross proceeds. In exchange, it agreed to issue new unregistered warrants covering 1,591,738 ADSs, plus placement-agent warrants covering another 55,711 ADSs.

What improved? Near-term cash pressure eased. What worsened? The dilution overhang. This is classic micro-cap biotech financing. Time is purchased through a capital structure that becomes even more sensitive to future share price behavior. On a quick read, the transaction may look like a vote of confidence from an existing holder who chose to exercise. In practice, it also says the company had to reopen the warrant economics in order to get the cash in.

Efficiency, Profitability and Competition

The key insight here is that Can-Fite should not be read through classical margins. It should be read through the quality of its revenue and the quality of its spending. At this stage, the question is not how much profit the company generates from each dollar of sales. The question is whether each dollar burned is moving the company toward a real proof point or merely delaying the next capital raise.

Revenue does not mean demand

$0.405 million of revenue in 2025 is almost symbolic, and that is the right instinct. This is not the beginning of commercialization. It is slow accounting recognition of upfront partner payments under legacy distribution agreements. The company explicitly treats those contracts as a single performance obligation satisfied over time through its research and development services. At year-end 2025 it still carried $1.58 million of deferred revenue, and for some agreements it estimates service completion dates as late as the end of 2029.

That distinction matters. Anyone looking only at the top line could mistakenly think a business base is starting to form. It is not. There are no product sales, no recurring end-market demand, and no evidence yet of commercial conversion. This is accounting revenue, not market revenue.

The concentration data adds another layer. Ewopharma accounted for 51% of 2025 reported revenue, CKD and Gebro each for 19%, and Cipher for 11%. But because the absolute number is so small, this is concentration of accounting recognition, not concentration of a live commercial business. It is easy to confuse the number of named partners with the number of active economic engines. For now, those are not the same thing.

The spending base has already chosen a side

The expense side is much clearer. Research and development expense rose to $6.69 million in 2025, up 16.3%, while general and administrative expense rose to $3.66 million, up 20.2%. Management says the increase in G&A was driven mainly by investor-relations spending tied to a one-time project in the first half of the year. That matters less than the deeper allocation signal.

Out of $5.39 million of direct project costs in 2025, about $4.12 million, roughly three quarters, went to Namodenoson. Only $1.28 million went to Piclidenoson. So while the corporate narrative is still spread across several fronts, the cash deployment in 2025 had already leaned clearly toward the liver and metabolic Namodenoson axis.

That is important because historically Piclidenoson absorbed the larger cumulative spend since inception, but the current year no longer looks like that. It suggests an internal shift in emphasis even if management does not frame it as a formal strategic turn. It is also worth noticing that the gap between total R&D expense of $6.69 million and direct project costs of $5.39 million leaves about $1.3 million of indirect support, payroll, facilities and overhead. In a company this small, that is not trivial.

The real competition is for partners and investor patience

The annual report explicitly lists crowded competitive fields in psoriasis, MASH and pancreatic cancer, with larger and better funded peers. But for Can-Fite the competition is not only scientific. It is also a competition for partner interest and investor patience. The company has no internal sales, marketing or distribution platform and does not expect to develop one itself. Its pitch is therefore not commercial muscle but a clinical package: oral dosing, favorable safety, and relatively low cost of goods.

That can matter, but it is not enough on its own. In crowded therapeutic markets, safety alone is not enough if efficacy remains only partially convincing. That is exactly why psoriasis is still interesting but not yet clean, and HCC is still promising but still conditional.

Cash Flow, Balance Sheet and Capital Structure

The right cash bridge is the all-in view

This story should be framed through all-in cash flexibility, not through normalized cash generation. The reason is simple. The thesis here is not about the recurring earning power of an existing commercial business. It is about whether the company can fund current operations until the next meaningful proof point. On that basis, year-end 2025 was not comfortable. Cash and short-term deposits totaled $8.54 million, against $8.95 million of operating cash outflow in 2025.

That is the gap that matters. Without financing, the company would not have comfortably covered another year at the 2025 burn rate. So the $9.64 million of financing inflow in 2025 is not a technical item, and the March 2026 raise is not a bonus. They are part of the current business model.

This is also why the balance sheet can look better than the underlying economics. Current assets of $9.44 million against current liabilities of $2.73 million look manageable, and there is no meaningful bank debt or covenant wall. But this is not a lender-driven story. It is a runway story. The real question is whether the company can keep spending close to $9 million a year without reopening the equity market under pressure. Right now, it cannot.

There is little financial debt, but heavy equity leverage

The balance sheet itself is not loaded with financial debt. Liabilities are mainly trade payables, deferred revenue and a relatively small lease liability. This is where the classic gap appears between “clean balance sheet” and “low risk.” In Can-Fite’s case, the pressure has migrated from debt to equity. At the end of 2025 the company already had 2.60 million warrants outstanding and another 49,533 options. After the balance-sheet date it added a new warrant layer through the March 2026 transaction.

That means the company’s real leverage is to the share price, not to a bank. The weaker the stock price, the more expensive the next financing becomes. The more expensive the next financing becomes, the more equity needs to be issued. The more equity is issued, the harder it becomes for a thinly traded stock to absorb the overhang. That loop is typical of micro-cap biotech, and it is already visible here.

The share count makes the point even more clearly. At December 31, 2025 the company had 2,618,425 issued and outstanding ordinary shares. In the beneficial ownership table dated March 25, 2026, the share base had already moved to 4,285,093 outstanding shares. Even before modeling the full future warrant stack, common shareholders had already absorbed a sharp expansion in the equity base within a short period.

The going-concern issue was bridged, not solved

One of the most interesting parts of the filing sits in the going-concern note. In the first step of the analysis, management itself lists the reasons for substantial doubt: a history of losses, persistent operating cash outflows, and dependence on additional financing to execute the R&D plan. Only in the second step, after considering $8.54 million of cash and deposits, approximately $4.35 million of post-balance-sheet gross proceeds, and a contingency plan involving program deferrals, reprioritization and cuts to key management compensation, does management conclude that the doubt is alleviated for the next twelve months.

That is an important analytical distinction. A surface read sees “enough liquidity for twelve months.” A fuller read shows that this conclusion relies on a post-balance-sheet capital event and on management’s willingness to slow or re-sequence the program stack if needed. That is not balance-sheet strength. That is a purchased bridge.

Outlook

Four non-obvious points should anchor the forward view:

1. 2026 looks like a bridge year, not a breakout year. The closest real event is pancreatic cancer in Q3 2026, while the two heavier proof points, psoriasis and HCC, sit in Q2 2027.
2. The nearest catalyst is also the one most vulnerable to over-interpretation. Safety in pancreatic cancer has already been demonstrated, but the market will want efficacy color or survival relevance.
3. The company’s most capital-intensive program, HCC, is still being carried by a Phase II subgroup signal rather than a whole-population win.
4. Even a positive readout is more likely to improve bargaining power with partners and investors first than to create immediate revenue.

In terms of year type, 2026 looks like a bridge year with one meaningful intermediate test. Pancreatic cancer can create momentum, but by itself it is unlikely to solve the funding question or turn the company into something with real commercial visibility. If Can-Fite can reach 2027 without another aggressive equity reset, that year becomes much more consequential, because two Phase III tracks are then supposed to produce more decisive market reads.

Management provides some outline for this path. It expects G&A to remain roughly at the 2025 level through 2026, but at the same time says it expects R&D expense to increase in the future as the programs advance. The implication is straightforward. Even if the overhead layer does not inflate further, the core burn problem does not disappear. Anyone expecting cash stabilization without a meaningful external event is leaning on too optimistic an assumption.

What has to happen over the next two to four quarters for the thesis to improve? First, the pancreatic data needs to show more than mere safety. Second, psoriasis and HCC need to keep advancing without visible disruption from the contingency plan. Third, MASH has to keep moving, otherwise it risks becoming another broad narrative lane that consumes cash before it proves anything. Fourth, if another financing is needed, it has to come in a way that does not further damage trading depth and investor confidence.

The deeper point is that even in a positive scenario, most of the value created at the next step would still be option value, not immediately accessible value. A clinical success would likely improve partnership leverage, funding terms and risk perception before it improves revenue. So the real question is not just whether there is a catalyst, but what kind of catalyst it is: one that moves the company closer to approval, one that moves it closer to a partnership, or one that merely extends the equity story by a few more quarters.

Risks

Financing risk remains central

This is still the heaviest risk. The company burns cash at roughly the same annual scale as the liquid resources it had at year-end, and it is doing so well before profitability or commercialization. That means that even after the March 2026 financing, any delay in trials, any slower enrollment, or any weaker capital-markets window can push dilution back to the center quickly.

The clinical risk is not uniform across programs

In psoriasis, the risk is that the story remains “good enough to discuss, not strong enough to win.” In HCC, the risk is that a prior subgroup signal proves harder to replicate than hoped. In pancreatic cancer, the risk is that the market gets an intermediate read that is not enough to justify a larger next step. In MASH, the risk is mostly time and cost: it is a broad, expensive field where slow progress can consume capital well before it creates conviction.

Commercialization risk sits one layer above the trial data

Even if the data are good, the company still depends on external parties to turn them into commercialization. The absence of an internal sales and marketing platform is not just an operational detail. It means the company still needs someone else to fund or carry part of the next step. That dependence is both a strength and a weakness: it keeps the internal cost base lean, but it also limits Can-Fite’s ability to capture value on its own.

Liquidity, listing and short positioning

The annual report itself warns that the reverse split may hurt trading depth, and it also flags continuing NYSE American listing sensitivity. At the same time, the short data do not describe a stable fundamental short camp. They describe sharp technical spikes that disappeared quickly.

That matters for interpretation. When short float jumps to 49% and then falls back to zero within a short period, while SIR stays relatively low, the pattern looks more technical than thesis-driven. So the main pressure on the stock does not appear to come from a durable short case. It appears to come from dilution, shallow trading and listing risk.

Conclusion

Can-Fite enters 2026 with more real clinical content than it had before. That is the supportive side of the thesis. But the central bottleneck has not changed: the company still depends on the capital market to buy the time it needs to reach the proof points that could change the conversation. In the short to medium term, market interpretation will be driven less by the mere existence of the pipeline and more by whether pancreatic cancer produces a usable signal and whether the next financing, if needed, comes from a position of strength or pressure.

Current thesis: Can-Fite has built a more credible clinical calendar, but the capital structure is still strong enough to bridge, not to solve.

What changed: the company no longer relies on one distant promise. It now has a nearer pancreatic catalyst and two active Phase III paths. At the same time, the cost of time has risen through a heavier dilution and warrant overhang.

Counter thesis: one can argue that the company has already moved past the lowest point of risk because it now has more advanced trials, better defined catalysts, a good safety profile, existing partners and cash raised after the balance sheet. In that scenario, one positive readout could materially improve financing terms.

What could change the market reading in the short to medium term: the Q3 2026 pancreatic cancer data, the stated execution pace in the Phase III programs, and the way management handles funding if the capital-markets window remains weak.

Why this matters: in a pre-revenue biotech, capital structure matters almost as much as the science in determining whether common shareholders can reach the proof point without being diluted away on the road to it.

What must happen next: pancreatic cancer needs to produce a read that goes beyond safety, psoriasis and HCC need to move forward without material delays, and any future financing, if required, needs to look like a choice rather than a forced concession.